Osprey Pharmaceuticals U.S.A. has raised $11 million in a first round of funding, according to VentureWire. The San Francisco company’s protein therapeutics treatment targets kidney disease. Burrill & Co. led the round, with participation from BDC Venture Capital, GeneChem Therapeutics Venture Fund, Novo Nordisk Biotech Fund, Western Technology Seed Investment Fund and Yasuda Enterprise Development.